Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334399 | 0.91 | CCKBR (0.37) | CCKBREPHX2FKBP1AFAAHCNR2 | |
| SCHEMBL6331005 | 0.88 | TSHR (0.39) | CCKBREPHX2FKBP1A | |
| SCHEMBL7045618 | 0.85 | CCKBR (0.39) | CCKBREPHX2FKBP1AFAAHCNR2 | |
| SCHEMBL6330066 | 0.81 | CCKBR (0.35) | CCKBREPHX2FKBP1AFAAHCNR2 | |
| SCHEMBL6334504 | 0.79 | TSHR (0.40) | CCKBREPHX2FKBP1A | |
| SCHEMBL6338565 | 0.73 | SMN1; SMN2 (0.40) | CCKBRFAAHCNR2HPGD | |
| SCHEMBL6340323 | 0.73 | SMN1; SMN2 (0.42) | CCKBREPHX2FAAHCNR2HPGD | |
| SCHEMBL6334377 | 0.67 | CCKBR (0.33) | CCKBREPHX2 | |
| SCHEMBL1477271 | 0.66 | TRPV6 (0.47) | EPHX2FAAHCNR2CNR1HPGD | |
| SCHEMBL6339911 | 0.64 | CCKBR (0.44) | CCKBREPHX2FKBP1AFAAHCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878734-B2 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-23 | — | — | US | disclosed |
| WO-2001085723-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (II) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199565-A1 | Gastrin and cholecystokinin receptor ligands(II) | GRPR, CCKBR, GIPR | CCKBR 2/4885EPHX2 2106/4885FKBP1A 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.